Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
To read the full story
Related Article
- Pfizer Japan Seeks Lupus Nephritis Nod for Rituxan Biosimilar
June 6, 2023
- Lucentis Biosimilar Now Approved for Diabetic Macular Edema
January 16, 2023
- 1st Lucentis Biosimilar Launched in Japan, Senju Eyes 6.9 Billion Yen in 5th Year
December 10, 2021
- With First Ophthalmologic Biosimilar Set to Debut, Specialist Says Close Attention Required for Unexpected Side Effects
December 9, 2021
- 1st Lucentis Biosimilar, 3rd Humira Follow-On Get Japan Listing
November 24, 2021
- Senju Gearing Up to Grow Lucentis Biosimilar into Its Mainstay Product
November 1, 2021
- Lucentis Biosimilar Filed in Japan; Senju/Gene Techno Eye 2021 Approval
September 23, 2020
- Gene Techno CEO Eyes Lucentis Biosimilar Launch in November 2021, Expects Share of “At Least 30%”
April 23, 2020
- Pfizer Rolls Out Japan’s Second Rituxan Biosimilar
January 21, 2020
BUSINESS
- Astellas’ FY2023 Operating Profit Tumbles 80% Due to Iveric Bio Buyout
April 26, 2024
- Daiichi Sankyo Ups FY2025 Sales Goal to 2.1 Trillion Yen on Bullish Cancer Biz
April 26, 2024
- Ono Ties Up with PRISM BioLab in Oncology Drug Discovery
April 26, 2024
- Argenx Seeks Label Expansion for Vyvdura in Japan
April 26, 2024
- Janssen Files Tremfya for Ulcerative Colitis in Japan
April 26, 2024
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…